MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.67 (13.06% downside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2015Janney Montgomery ScottBoost Price TargetBuy$15.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015Chardan CapitalBoost Price TargetBuy$14.00 -> $17.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015Cowen and CompanyReiterated RatingOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Chardan CapitalInitiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2015Leerink SwannSet Price TargetBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015Leerink SwannBoost Price TargetOutperform$9.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015Janney Montgomery ScottInitiated CoverageBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014JPMorgan Chase & Co.Boost Price TargetOverweight$8.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/20/2014Cowen and CompanyBoost Price Target$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2014Janney Montgomery ScottUpgradeNeutral -> Buy$2.50 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2014Leerink SwannUpgradeMarket Perform -> Outperform$2.50 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2014JPMorgan Chase & Co.UpgradeNeutral -> OverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2014Leerink SwannLower Price Target$3.00 -> $2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Leerink SwannBoost Price Target$2.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2013Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2013JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/24/2013Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/4/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha